ALLR — Allarity Therapeutics Income Statement
0.000.00%
- $4.30m
- $8.19m
Annual income statement for Allarity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.12 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17.7 | 8.43 | 26.7 | 34.5 | 17.1 |
Operating Profit | -17.6 | -8.43 | -26.7 | -34.5 | -17.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19 | -6.42 | -26.5 | -17.6 | -11.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.4 | -6.62 | -26.6 | -16.1 | -11.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -14.3 | -6.6 | -26.6 | -16.1 | -11.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.3 | -6.6 | -26.6 | -21.1 | -20.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -32,738 | -22,648 | -119,816 | -31,704 | -205 |